SecBot SecBot

CGON drug pipeline

CG Oncology, Inc. · 1 rated drug
$84.78
+13.9% 1-day · Nov 16
Next catalyst
None dated
Newer dates for subscribers
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 bullish
Phase 3 trials
1
0 with results posted

Upcoming catalysts

0 dated

1 newer catalyst for subscribers. See plans

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3
Time to marketBLA submission planned for Q4 2026 in BCG-unresponsive NMIBC. If accepted and approved under standard FDA review, potential approval could come in H2 2027. The drug already has Breakthrough Therapy designation from the FDA.

cretostimogene cretostimogene grenadenorepvec Updated Sep 2

What to watch

Watch for BLA submission completion in Q4 2026, this is the key catalyst that will determine whether cretostimogene becomes the first FDA-approved oncolytic virus therapy for NMIBC. Also monitor PIVOT-006 Phase 3 topline data (intermediate-risk NMIBC), which could be imminent. The $1.05B ATM facility creates ongoing dilution overhang, so positive regulatory catalysts are needed to offset that pressure.

Bull case
  • Phase 3 BOND-003 data published in The Lancet Oncology showed 75.5% complete response rate with median 27.9-month durability and zero Grade 3+ treatment-related adverse events, a compelling efficacy/safety profile in a high-need indication with no approved bladder-sparing alternatives beyond cystectomy
  • Analyst consensus is overwhelmingly bullish: 19 Buy/Strong Buy ratings vs 2 Hold, mean price target $91.08 implying ~18.6% upside from $75.86, with recommendation mean of 1.4
  • Strong institutional ownership with major holders including RTW Investments ($605M), BlackRock ($445M), and Wellington ($378M) as of Q2 2026; multiple funds added or doubled positions in the quarter
Bear case
  • Massive $1.05B ATM equity offering (upsized by $500M in August 2026) creates significant dilution overhang, up to ~7.8% additional shares at current prices, with $550M already sold via 10.8M shares
  • Short interest of ~12.7% of shares outstanding with 14.85 days to cover reflects persistent bearish sentiment; daily short-volume ratio consistently elevated (signal: elevated on most recent sessions)
  • Insider selling via 10b5-1 plans: Director Leonard Post sold shares in July and August 2026, Director James Mulay sold $1.82M in July 2026

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
cretostimogeneA Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTPhase 3Active not recruiting367Jun 2026